The New England
DRUG METABOLISM DISCUSSION GROUP
Winter Quarterly Meeting
Thursday, December 5th, 2019
TAKEDA PHARMACEUTICALS COMPANY,
35 Landsdowne Street, Cambridge, MA 02139
The Drug Metabolism Scientist’s Contribution to the Development of Gene Therapies: It’s not what you do, it’s the way that you do it
Executive Director, PK Sciences, Global Head Ophthalmology TA,
Novartis Institutes for BioMedical Research, Inc.
Although in vivo, viral-based, Gene Therapies have been studies by academia for many decades it is only in the past 5-10 years that a significant number of these therapies have entered Clinical trials under the sponsorship of Biotech and Pharmaceutical companies. The involvement of these companies in the development of in vivo Gene Therapies has required the drug metabolism scientists to adapt the approaches and mindsets that have served them well for developing LMW and Biologics. This presentation will provide an overview of what a traditional DMPK organization can contribute to the development of a Gene Therapy, describe how that support is currently provided, and offer insights into alternative, and hopefully better, ways of providing that support.
The cocktail hour will begin at 5:30 PM, dinner at 6:30 PM and the presentation at 7:30 PM.
If you need a 'Special Food Request' contact:
The deadline for reservations or cancellations is 4pm, December 2nd, 2019
********NO WALK-IN OR LATE REGISTRATION ACCEPTED********